Introduction {#s1}
============

The burden of cancer continues to increase globally. According to WHO statistics, cancer is the second leading cause of death, accounting for 8.8 million deaths in 2015 ([@B26]). Anticancer therapies, for instance, surgery, chemotherapy, radiotherapy, and targeted cancer immunotherapy, are examples on controlling cancer cell growth, prolonging survival time, and improving quality of life to some extent. However, these therapies either alone or in combination have been shown to have various limitations and can result in severe side effects, which include an increased risk of subsequent cancers and lowered quality of life that vary with clinical factors (e.g., cancer type and treatment) and patient characteristics (e.g., age, sex, and comorbidity) ([@B8]; [@B48]; [@B17]).

In the past few decades, *Coriolus versicolor* (taxonomic name, *Trametes versicolor*; Chinese name; *Yun Zhi*) and its related mushrooms recorded in traditional Chinese medicine (TCM) literature have found their way to the market in Asian countries as anticancer remedies, and potentially play an important role in the whole course of cancer treatment such as the recovery stage of post-operation, and the stages during and after radiotherapy or chemotherapy ([@B31]; [@B47]). However, they have long been clinically confused based on their similar appearance and nature of medicinals according to the TCM theory ([@B28]). *In vitro* studies suggested that both *C. versicolor* (*Yun Zhi*) and *Ganoderma lucidum* (*Ling Zhi*) extracts, for instance, polysaccharide krestin (PSK), polysaccharide peptide (PSP) in *C. versicolor*, and beta-glucans, triterpenes in *G. lucidum*, possess selective cytotoxic activity against certain tumor cells ([@B41]; [@B4]; [@B10]). They may also activate various types of immune effector cells to enhance their anticancer activity, for instance, B lymphocytes, T lymphocytes, cytotoxic T cells, natural killer cells, and lymphokine activated killer cells ([@B40]; [@B42]). Furthermore, significant reduction of the tumor size after prolonged administration with the extracts was clearly shown in mice and the extract appeared to be effective for the prophylaxis against cancers ([@B37]; [@B30]; [@B3]).

Compared to the supporting evidence from laboratory and animal tests, human trial of *Yun Zhi* and *Ling Zhi* extracts is just having its start. In the past 40 years, trials were mainly conducted on patients in Asia with breast cancer, colorectal cancer, gastric cancer, and non-small cell lung cancer, etc. and the trial data were scattered in regional databases ([@B34]; [@B22]; [@B35]; [@B12]). Also, there was no systematic review to integrate the outcome measurements in different trials to form strong evidence. As a result, in order to provide better understanding of their clinical effect for physicians and other health care providers, we summarized trial results using *C. versicolor* and *G. lucidum* related natural products as adjuvant cancer treatment in different stages and kinds of cancer lesions from various databases. We hope this review can contribute a comprehensive view of current existing evidence to facilitate development of more effective natural products for public good.

Methods {#s2}
=======

Search Strategy {#s2_1}
---------------

The systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines ([@B20]). We searched PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Database, and Chinese Scientific Journal Database (VIP) from inceptions to May 10, 2019, and identified randomized controlled trials with *C. versicolor* and *G. lucidum* related natural products for cancer patients. The search strategy was conducted by medical subject headings with text words. We referred to the published Cochrane protocol about *C. versicolor* and *G. lucidum* to initiate our search strategies ([@B29]). We also consulted all the searching names with the Chinese Medicine pharmacists in mainland China and Hong Kong. The completed search terms about *C. versicolor* and *G. lucidum* included as follows: *C. versicolor*, *T. versicolor*, *Polyporus* *versicolor*, *Polystictus versicolor*, Kawaratake, *Yun Zhi*, *Ling Zhi*, polysaccharide-K, PSK, krestin, polysaccharopeptide, polysaccharide-peptide, PSP, VPS, turkey tail, cloud mushroom, and unji mushroom.

In addition, the reference lists of the included studies were also checked, so as to supplement possible relevant literatures.

Study Selection {#s2_2}
---------------

Two reviewers independently screened and selected the searched articles according to the inclusion criteria (LZ and PY): 1) patients with cancer confirmed by pathology; 2) *C. versicolor* and *G. lucidum* related natural products were used as an intervention alone or combined with other drugs, without limitation on drug regimen, dosage and, course of treatment; and 3) must be randomized controlled trials. The following articles were excluded: 1) case series or reviews and conference abstracts; 2) valid original data were unable to obtain even when contacting the author; and 3) similar studies were reported without additional data to analyze and extract.

Data Extraction {#s2_3}
---------------

Two reviewers (LZ and PY) independently extracted data on participant characteristics from the selected studies in a standardized data extraction form. We extracted the following information from each included article: first author, year of publication, country, the type of tumor, number of participants, participant characteristics, the characteristics of the products (the type, dose, start time, duration of therapy), mean follow-up duration, number of dropout, controlled intervention, and outcome data.

Definition of Outcomes {#s2_4}
----------------------

We included three primary outcomes to compare the effectiveness and safety of *C. versicolor* and *G. lucidum* related natural products for cancer in the analysis: 1) overall survival (OS); 2) relapse-free survival (RFS) rate; and 3) clinical efficacy. OS and RFS are defined by the individual study. Clinical efficacy was evaluated by investigators using Macdonald criteria ([@B16]). There were four "response" categories: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Total efficacy means CR+PR; control rate means CR+PR+SD.

The secondary outcomes recorded were 1) immune-modulating effects including cluster of differentiation 3 (CD3); cluster of differentiation 4 (CD4); cluster of differentiation 8 (CD8); CD4/CD8; and natural killer cell (NK); 2) the post-treatment Karnofsky Performance Status (KPS) Score Change; and 3) adverse events. The post-treatment KPS score change was divided into obvious effectiveness (had an improvement of more than 20 points in the KPS score), effectiveness (an improvement of more than 10 points), stabilization (an improvement of less than 10 points or had no change), and invalid (a decrease in KPS score). Total effectiveness means obvious effectiveness plus effectiveness ([@B46]).

Risk of Bias Assessment {#s2_5}
-----------------------

Two review authors (LZ and PY) assessed potential risks of bias for all included studies using the Cochrane's tool for assessing risk of bias ([@B7]). The tool assesses bias in six different domains: sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias. Each domain receives a score of high, low, or unclear depending on each review author's judgment. A third review author acted as an adjudicator in the event of disagreement. Where doubt existed as to a potential risk of bias, we contacted the study authors for clarification.

Statistical Analysis {#s2_6}
--------------------

In this meta-analysis, risk ratio (*RR*) and 95% confidence interval (*CI*) were considered as the effect size for dichotomous outcomes; weighted mean differences (WMD) with 95% *CI* were calculated as the effect size for continuous outcomes. For time-to-event data, we will pool hazard ratio (*HR*). Forest plots were produced to visually assess the effect size and corresponding 95% *CI* using random-effects models. Heterogeneity between studies was assessed *via* the forest plot, while *I* *^2^* values described the total variation between studies. *I* *^2^* values of \<25%, 25--50%, and \>50% indicated low, moderate, and high heterogeneity, respectively. Subgroup analyses were used to explore and interpret the sources of heterogeneity; to evaluate whether the effects were modified by treatment characteristics, we specified based on experiment type and cancer type. We used sensitivity analyses to explore and interpret the sources of high heterogeneity ([@B7]). Funnel plots, Begg's test ([@B1]), and Egger's test ([@B5]) would be adopted to detect publication bias only when there are at least 10 studies reporting the primary outcomes, because when there are fewer studies the power of the tests is too low to distinguish chance from real asymmetry ([@B7]). Statistical analysis was performed with STATA software, version 13.0 (StataCorp, College Station, TX).

Results {#s3}
=======

Studies Selection {#s3_1}
-----------------

Our literature search yielded 1,616 trials *via* electronic databases, and 26 trials by hand research. After removing duplicates records, 1,360 trials were screened, and 1,302 trials were excluded by reviewing titles and abstracts. The remaining 58 trials were reviewed by full text. Eventually, 23 trials involving 4,246 cancer patients were included in this work. Study selection flow is detailed by PRISMA flow diagram as shown in [**Figure 1**](#f1){ref-type="fig"}. All the preparations of *C. versicolor* and *G. lucidum* related natural products in each included article were listed in [**Supplement 1**](#SM3){ref-type="supplementary-material"}.

![Flow chart.](fphar-10-00703-g001){#f1}

Description of Trials Identified {#s3_2}
--------------------------------

[**Table 1**](#T1){ref-type="table"} presents the characteristics of the 23 included trials ([@B23]; [@B6]; [@B34]; [@B33]; [@B22]; [@B24]; [@B21]; [@B32]; [@B19]; [@B13]; [@B35]; [@B38]; [@B11]; [@B15]; [@B39]; [@B43]; [@B14]; [@B45]; [@B9]; [@B44]; [@B2]; [@B18]; [@B25]). All the trials used *C. versicolor* related natural products (n = 14) ([@B23]; [@B6]; [@B34]; [@B33]; [@B22]; [@B24]; [@B21]; [@B32]; [@B35]; [@B38]; [@B39]; [@B2]; [@B18]; [@B25]) or *G. lucidum* related natural products (n = 9) ([@B19]; [@B13]; [@B11]; [@B15]; [@B43]; [@B14]; [@B45]; [@B9]; [@B44]). The majority of trials were from China ([@B32]; [@B19]; [@B13]; [@B35]; [@B38]; [@B11]; [@B15]; [@B39]; [@B43]; [@B14]; [@B45]; [@B9]; [@B44]), whereas eight papers were from Japan ([@B23]; [@B34]; [@B33]; [@B22]; [@B24]; [@B21]; [@B18]; [@B25]), one paper was from in Taiwan ([@B6]), and one from Singapore ([@B2]). Almost half of the 23 trials were published in Chinese ([@B32]; [@B19]; [@B13]; [@B38]; [@B11]; [@B15]; [@B39]; [@B43]; [@B14]; [@B9]; [@B44]), the others were published in English ([@B23]; [@B6]; [@B34]; [@B33]; [@B22]; [@B24]; [@B21]; [@B35]; [@B45]; [@B2]; [@B18]; [@B25]). In 23 trials, 5 included non-small cell lung cancer (NSCLC) patients ([@B35]; [@B15]; [@B43]; [@B9]; [@B44]), 3 included breast cancer patients ([@B33]; [@B21]; [@B12]; [@B45]), 4 included gastric cancer patients ([@B23]; [@B22]; [@B32]; [@B38]), 4 included colorectal cancer patients ([@B34]; [@B39]; [@B14]; [@B18]), 3 included nasopharyngeal carcinoma patients ([@B6]; [@B19]; [@B13]), and the other 4 trials included esophageal cancer ([@B24]), rectal cancer ([@B25]), gastrointestinal cancer ([@B11]), and hepatocellular carcinoma patients ([@B2]), respectively. The range duration of therapy was 1 to 24 months.

###### 

Characteristics of the included trials and participants.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author   Year   Country     Language   Survey year        Cancer type                        TNM stage   KPS    No. of subject   Gender (M/F)   Age median (range)   Experiment   Start time                                              Daily dosage (/d)   Duration (year)   Control Group   Follow-up (year)   Dropout (T/C)
  -------- ------ ----------- ---------- ------------------ ---------------------------------- ----------- ------ ---------------- -------------- -------------------- ------------ ------------------------------------------------------- ------------------- ----------------- --------------- ------------------ ---------------
  [@B45]   2012   China       English    2009/6--2010/9     Breast cancer                      I∼IIIA      NA     48               NA             52.2\                GL           NA                                                      1g                  1/6               RT+CT+placebo   1/12               0/0
                                                                                                                                                  (NA)                                                                                                                                                               

  [@B21]   1996   Japan       English    1985/2--1988/3     Breast cancer (ER(+))              II          NA     350              NA             52\                  PSK^a^       2 weeks after surgery                                   3g                  2                 CT only         5                  8/4
                                                                                                                                                  (28--74)                                                                                                                                                           

  [@B21]   1996   Japan       English    1985/2--1988/3     Breast cancer (ER(+))              II          NA     347              NA             54\                  PSK^b^       2 weeks after surgery:                                  3g                  2                 CT only         5                  8/3
                                                                                                                                                  (28--75)                                                                                                                                                           

  [@B21]   1996   Japan       English    1985/2--1988/3     Breast cancer (ER(-))              II          NA     364              NA             52\                  PSK^c^       2 weeks after surgery:                                  3g                  2                 CT only         5                  4/8
                                                                                                                                                  (27--75)                                                                                                                                                           

  [@B33]   1992   Japan       English    1982/10--1985/1    Breast cancer (IIA+T2N1, ER(-))    IIA∼IIIA    NA     278              NA             49.5\                PSK          2 weeks after surgery:                                  3g                  2                 CT only         5                  NA
                                                                                                                                                  (NA)                                                                                                                                                               

  [@B33]   1992   Japan       English    1982/10--1985/1    Breast cancer (IIIA+T3N0, ER(-))   IIA∼IIIA    NA     81               NA             48.6\                PSK          2 weeks after surgery:                                  3g                  2                 CT only         5                  NA
                                                                                                                                                  (NA)                                                                                                                                                               

  [@B25]   2018   Japan       English    2011/10--2013/2    Rectal cancer                      II          NA     106              NA             50.1\                PSK          After surgery                                           3g                  1                 Surgery alone   5                  2/3
                                                                                                                                                  (NA)                                                                                                                                                               

  [@B18]   2018   Japan       English    2006/3--2010/12    Colorectal cancer                  IIB∼III     NA     351              167/184        65.5\                PSK          At the same time as chemotherapy                        3g                  1                 CT+leucovorin   5                  4/2
                                                                                                                                                  (35--80)                                                                                                                                                           

  [@B14]   2011   China       Chinese    2010/5--2011/3     Colorectal cancer                  III∼IV      ≥70    30               17/13          44\                  GL           At the same time as chemotherapy                        30g                 2 cycles          placebo         NA                 0/0
                                                                                                                                                  (18--75)                                                                                                                                                           

  [@B39]   2008   China       Chinese    2003/6--2005/6     Colorectal cancer                  III∼IV      \>60   53               31/22          61\                  PSK          NA                                                      6g                  1/12              CT only         NA                 0/0
                                                                                                                                                  (41--71)                                                                                                                                                           

  [@B34]   1990   Japan       English    NA                 Colorectal cancer                  III∼IV      NA     111              NA             58.9\                PSK          10--15 days after surgical operations                   3g                  1/6               CT+placebo      10                 5/4
                                                                                                                                                  (34--86)                                                                                                                                                           

  [@B24]   1995   Japan       English    NA                 Esophageal cancer                  I∼IV        NA     69               60/9           61.4\                PSK          NA                                                      3g                  1/4               RT only         5                  0/0
                                                                                                                                                  (44--82)                                                                                                                                                           

  [@B24]   1995   Japan       English    NA                 Esophageal cancer                  I∼IV        NA     105              94/11          58.1\                PSK          NA                                                      3g                  1/4               RT+CT\          5                  0/0
                                                                                                                                                  (41--77)                                                                                                                        only                               

  [@B38]   2003   China       Chinese    1997/1--2000/4     Gastric cancer                     III         \>50   126              78/48          61.3\                PSK          2 weeks after surgery                                   6 grain             2                 CT only         5                  6/8
                                                                                                                                                  (36--71)                                                                                                                                                           

  [@B22]   1994   Japan       English    1985/7--1987/6     Gastric cancer                     I∼IV        NA     253              169/84         58.5\                PSK          2 week after surgery                                    3g                  1/6               CT only         7                  0/0
                                                                                                                                                  (27--75)                                                                                                                                                           

  [@B23]   1988   Japan       English    NA                 Gastric cancer                     NA          NA     390              NA             NA\                  PSK^d^       1--2 weeks after surgery                                3g                  1                 CT only         5                  24/16
                                                                                                                                                  (NA)                                                                                                                                                               

  [@B23]   1988   Japan       English    NA                 Gastric cancer                     NA          NA     388              NA             NA\                  PSK^e^       1--2 weeks after surgery                                3g                  1                 CT only         5                  21/16
                                                                                                                                                  (NA)                                                                                                                                                               

  [@B32]   1996   China       Chinese    NA                 Gastric cancer                     I∼IV        NA     30               NA             NA\                  PSP          12--16 days after surgery                               3 grain             1/6               CT+Bieganchun   1/6                NA
                                                                                                                                                  (NA)                                                                                                                                                               

  [@B11]   2007   China       Chinese    2000/2--2004/12    Gastrointestinal cancer            NA          NA     82               NA             56.3\                GL^§^        NA                                                      4.5g                1/2               CT only         1/2                0/0
                                                                                                                                                  (NA)                                                                                                                                                               

  [@B11]   2007   China       Chinese    2000/2--2004/12    Gastrointestinal cancer            NA          NA     62               NA             56.3\                GL^¶^        NA                                                      150ml               1/2               CT only         1/2                0/0
                                                                                                                                                  (NA)                                                                                                                                                               

  [@B2]    2017   Singapore   English    NA                 Hepatocellular carcinoma           NA          NA     15               14/1           61\                  CV           NA                                                      2.4g                1/2               RT+CT+placebo   NA                 0/0
                                                                                                                                                  (48--74)                                                                                                                                                           

  [@B19]   1999   China       Chinese    NA                 Nasopharyngeal carcinoma           I∼IV        ≥80    72               67/5           NA\                  GL           At the same time as radiotherapy                        2.28g               1/12              RT+Vitamia      1/12               0/0
                                                                                                                                                  (18--60)                                                                                                                                                           

  [@B13]   2002   China       Chinese    1994/07--1999/01   Nasopharyngeal carcinoma           NA          NA     198              137/61         NA\                  GL           At the same time as radiotherapy                        1.2g                1/12              RT only         3                  1/4
                                                                                                                                                  (NA)                                                                                                                                                               

  [@B6]    1989   Taiwan      English    1981/10--1986/10   Nasopharyngeal carcinoma           I∼IV        ≥50    34               26/8           46.5\                PSK          Within 1 month of the completion of primary treatment   1g                  1/12--2           RT only         5                  4/0
                                                                                                                                                  (NA)                                                                                                                                                               

  [@B44]   2015   China       Chinese    2011/2--2014/3     NSCLC                              III∼IV      ≥60    59               40/19          64.1\                GL           At the same time as chemotherapy                        12 grain            1/2               CT+placebo      NA                 0/0
                                                                                                                                                  (39--76)                                                                                                                                                           

  [@B15]   2008   China       Chinese    2001--2006         NSCLC                              NA          \>60   56               33/23          45.1\                GL           NA                                                      10g                 1/4--1/3          CT only         3+1/3              0/0
                                                                                                                                                  (28--62)                                                                                                                                                           

  [@B43]   2010   China       Chinese    NA                 NSCLC                              III∼IV      NA     60               39/21          64.2\                GL           NA                                                      1 dose              2/3               CT only         NA                 0/0
                                                                                                                                                  (NA)                                                                                                                                                               

  [@B9]    2013   China       Chinese    2011/11--2013/4    NSCLC                              III∼IV      ≥60    60               38/22          58.8\                GL           NA                                                      10g                 2/3               CT only         1                  0/0
                                                                                                                                                  (18--70)                                                                                                                                                           

  [@B35]   2003   China       English    1999/12--2001/4    NSCLC                              III∼IV      ≥60    68               45/23          58.3\                PSP          NA                                                      3 capsules          1/12              CT+placebo      1/12               2/8
                                                                                                                                                  (34--75)                                                                                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PSK, Polysaccharide Krestin; PSP, Polysaccharide Peptide; GL, Ganoderma lucidum; CV, Coriolus versicolor; RT, Radiotherapy; CT, Chemotherapy; NA, not available; NSCLC, Non-small cell lung cancer; M, male; F, female; CT, chemotherapy; RT, radiotherapy; ER(-), estrogen receptor-negative; ER(+), estrogen receptor positive; T, treatment; C, control; *§*, capsule; ¶, oral liquid; a, Stage IIA ER(+), CV+ mitomycin C (MMC) + tamoxifen (TAM) vs. MMC+TAM+ futraful (FT); b, CV+MMC+TAM vs. MMC+TAM; c, Stage IIA ER(-), CV+MMC vs. MMC+FT; d, CV + MMC +FT vs. MMC+FT; e, CV +MMC vs. MMC+FT.

The data in five trials were split into two or three records because there were two kinds of comparison, dosage form or disease staging. The data were split into two records because of the comparison in Ogoshi K's trial ([@B24]) \[*C. versicolor* + radiotherapy (RT) vs. RT only and *C. versicolor* + RT + chemotherapy (CT) vs. RT + CT only\] and in Niimoto M's trial ([@B23]) \[*C. versicolor*+ mitomycin C (MMC)+futraful (FT) vs. MMC+FT and *C. versicolor*+MMC vs. MMC+FT\]; because of the dosage form in Junjie Jing's trial ([@B11]) (capsule and oral liquid); because of the disease staging in Toi M's trial ([@B33]) (stage IIA+T2N1, ER\[-\], and stage IIIA+T3N0,ER\[-\]). The data were split into three records because of the comparison and disease staging in Morimoto T's trial ([@B21]) (stage IIA ER\[-\]:*C. versicolor*+MMC vs. MMC+FT; stage IIA ER\[+\]:*C. versicolor*+MMC+ tamoxifen \[TAM\] vs. MMC+TAM+FT and *C. versicolor*+MMC+TAM vs. MMC+TAM). Therefore, there were 27 records to be analyzed.

[**Figures S1**](#SM1){ref-type="supplementary-material"} **and** [**S2**](#SM2){ref-type="supplementary-material"} in the Supplement show the assessment of the risk of bias. All studies were randomized; four studies were double-blinded design; five studies were placebo-controlled trials; six trials described an adequate random sequence generation process; and four trials described the methods used for allocation concealment.

Effects on Overall Survival {#s4}
===========================

Seventeen trials involving 3,682 cancer patients compared the effect on survival. Compared with control treatment, using of *C. versicolor* and *G. lucidum* related natural products was associated with a lower risk of mortality (*HR*: 0.82 95% *CI*: 0.72, 0.94; *P* = 0.005). Subgroup analysis for experiment type showed this effect was consistent for trial using *C. versicolor* related natural products (*HR*: 0.83; 95% *CI*: 0.71, 0. 98; *P* = 0.030, 16 studies), but no difference was found in trial using *G. lucidum* related natural products (*HR*: 0.81; 95% *CI*: 0.62, 1.07; *P* = 0.139; three studies) ([**Figure 2**](#f2){ref-type="fig"}).

![Meta-analysis results of overall survival.](fphar-10-00703-g002){#f2}

Subgroup analysis for cancer type showed, compared with control treatment, trials using *C. versicolor* and *G. lucidum* related natural products were associated with lower risk of mortality in gastric cancer (*HR*: 0.74; 95% *CI*: 0.62,0.87; *P* = 0.001; four trials) and nasopharyngeal carcinoma (*HR*: 0.68; 95% *CI*: 0.56,0.84; *P* \< 0.001; two trials). However, no differences were found in breast cancer (*HR*: 0.95; 95% *CI*: 0.65,1.40; *P* = 0.798; five trials), colorectal cancer (*HR:* 1.22; 95% *CI:* 0.46, 3.21; *P* = 0.694; two trials), esophageal cancer (*HR*: 0.84; 95% *CI*: 0.57,1.24; *P* = 0.387; two trials), hepatocellular carcinoma (*HR*: 0.35; 95% *CI*: 0.10,1.23; *P* = 0.101; one trial), NSCLC (*HR*: 0.99; 95% *CI*: 0.71,1.38; *P* = 0.953; two trials), and rectal cancer (*HR*: 1.82; 95% *CI*: 0.38,8.72; *P* = 0.454; one trial) ([**Table 3**](#T3){ref-type="table"}).

Effects on Relapse-Free Survival Rate {#s4_1}
-------------------------------------

Nine trials involving 1,155 cancer patients compared the effect on RFS rate. All nine trials used *C. versicolor* related natural products. As shown in [**Figure 3**](#f3){ref-type="fig"}, there was no significant association of *C. versicolor* related natural products with RFS (*HR*: 1.19; 95% *CI*: 0.91, 1.55; *P* = 0.2) compared with control treatment ([**Figure 3**](#f3){ref-type="fig"}). Subgroup analysis for cancer type showed, compared with control treatment, trials using *C. versicolor* and *G. lucidum* related natural products were associated with higher risk of relapse in gastric cancer (*HR*: 1.52; 95% *CI*: 1.01,2.30; *P* = 0.046; one trial). There were no significant associations of *C. versicolor* related natural products with risk of relapse in breast cancer (*HR*: 1.18; 95% *CI*: 0.89,1.57; *P* = 0.243; five trials), colorectal cancer (HR: 1.05; 95% CI: 0.42,2.58; *P* = 0.923; two trials), hepatocellular carcinoma (*HR*: 0.42; 95% *CI*: 0.13,1.36; *P* = 0.147; one trial), nasopharyngeal carcinoma (*HR*: 1.19; 95% *CI*: 0.45,3.10; *P* = 0.729; one trial), and rectal cancer (HR: 2.45; 95% CI: 0.99,6.06; *P* = 0.053; one trial) ([**Table 3**](#T3){ref-type="table"}).

![Meta-analysis results of relapse-free survival rate.](fphar-10-00703-g003){#f3}

Clinical Efficacy {#s4_2}
-----------------

Nine trials involving 1,883 cancer patients assessed the total efficacy. Compared with control treatment, using *C. versicolor* and *G. lucidum* related natural products was associated with a higher total efficacy (*RR*: 1.30; 95% *CI*: 1.09, 1.55; *P* = 0.003). Subgroup analysis for experiment type showed trials using *G. lucidum* related natural products with a higher total efficacy (*RR*: 1.31; 95% *CI*: 1.09, 1.58; *P* = 0.004; seven studies) compared with control treatment. However, there was no significant association of *C. versicolor* related natural products with total efficacy (*RR*: 1.20; 95% *CI*: 0.70, 2.06; *P* = 0.497) compared with control treatment. Only two trials used *C. versicolor* related natural products, and one of them was excluded because the total efficacy of the trial was 0% ([**Figure 4**](#f4){ref-type="fig"}).

![Meta-analysis results of total efficacy.](fphar-10-00703-g004){#f4}

Subgroup analysis for cancer type showed, compared with control treatment, trials using *C. versicolor* and *G. lucidum* related natural products were associated with a higher total efficacy in NSCLC (*RR*: 1.55; 95% *CI*: 1.12, 2.17; *P* = 0.009; five trials), but no differences were found in colorectal cancer (*RR*: 1.20; 95% *CI*: 0.71, 2.06; *P* = 0.497; one trial), gastrointestinal cancer (*RR*: 1.27; 95% *CI*: 0.79,2.04; *P* = 0.329; two trials), and nasopharyngeal carcinoma (*RR*: 1.16; 95% *CI*: 0.91, 1.47; *P* = 0.238; one trial) ([**Table 3**](#T3){ref-type="table"}).

Nine trials involving 1,883 cancer patients were compared with the control rate. There was no significant association of *C. versicolor* and *G. lucidum* related natural products and control rate (*RR*: 1.05; 95% *CI*: 0.96, 1.14; *P* = 0.321) compared with control treatment. Subgroup analysis for experiment type showed no significant interactions with experiment type for the primary outcome of control rate. Control rate did not differ significantly between trials using *G. lucidum* related natural products (*RR*: 1.05; 95% *CI*: 0.95, 1.15; *P* = 0.355; seven studies) or trials using *C. versicolor* related natural products (*RR*: 1.04; 95% *CI*: 0.85, 1.26; *P* = 0.725; two studies) and control treatment ([**Figure 5**](#f5){ref-type="fig"}).

![Meta-analysis results of control rate.](fphar-10-00703-g005){#f5}

Subgroup analysis for cancer type showed, compared with control treatment, trials using *C. versicolor* and *G. lucidum* related natural products were associated with a higher control rate in NSCLC (*RR*: 1.18; 95% *CI*: 1.04, 1.33; *P* = 0.009; five trials), but no differences were found in colorectal cancer (*RR*: 1.06; 95% *CI*: 0.80, 1.40; *P* = 0.684; one trial), gastrointestinal cancer (*RR*: 0.97; 95% *CI*: 0.75,1.26; *P* = 0.836; two trials), and nasopharyngeal carcinoma (*RR*: 0.90; 95% *CI*: 0.77, 1.05; *P* = 0.182; one trial) ([**Table 3**](#T3){ref-type="table"}).

Immunomodulating Effects {#s4_3}
------------------------

[**Table 2**](#T2){ref-type="table"} summarizes results of meta-analysis and subgroup analyses of the immunomodulating effects for *C. versicolor* and *G. lucidum* related natural products. Compared with control treatment, using *C. versicolor* and *G. lucidum* related natural products had a favorable effect on elevated levels of CD3 (*MD*: 9.03%; 95% *CI*: 2.10, 16.50; *P* = 0.011) and CD4 (*MD*: 9.2%; 95% *CI*: 1.01, 17.39; *P* = 0.028). However, no difference between *C. versicolor* and *G. lucidum* related natural products and control treatment was seen in the effect on the levels of CD8 (*MD*: -5.52%; 95% *CI*: -23.17, 12.13; *P* = 0.540) and CD4/CD8 (*MD*: 0.73; 95% *CI*: -0.45, 1.91; *P* = 0.227). In terms of NK, only two trials reported the NK\[9, 16\]; one trial used *G. lucidum* related natural products in a patient with colorectal cancer (MD: 3.04%; 95% *CI*: -1.76, 7.84; *P* = 0.215), while the other used *C. versicolor* related natural products in a patient with gastric cancer (*MD*: 10.29%; 95% *CI*: 2.07, 18.15; *P* = 0.014); there was no difference between *C. versicolor* and *G. lucidum* related natural products and control treatment in the effect on NK (*MD*: 5.87%; 95% *CI*: -1.06, 12.8; *P* = 0.097) ([**Tables 2**](#T2){ref-type="table"} and [**3**](#T3){ref-type="table"}).

###### 

Meta-analysis and subgroup analysis of immunomodulating effects and KPS for *Coriolus versicolor* and *Ganoderma lucidum* related natural products.

  Variable                   No. of trials   No. of Subject   Heterogeneity   MD/ RR   95% CI    *P* value                      
  -------------------------- --------------- ---------------- --------------- -------- --------- ----------- ------------------ ---------
  Immunomodulating effects                                                                                                      
  CD3 (%)                    3               106              109             94.9     \<0.001   9.30        (2.10, 16.50)      0.011
   *Ganoderma lucidum*       2               46               43              0.0      0.036     13.05       (10.37, 15.72)     \<0.001
   *Coriolus versicolor*     1               60               66              ---      ---       4.30        (3.63, 4.97)       \<0.001
  CD4 (%)                    3               106              109             96.4     \<0.001   9.20        (1.01,17.39)       0.028
   *Ganoderma lucidum*       2               46               43              0.0      0.362     13.19       (10.55, 15.82)     \<0.001
   *Coriolus versicolor*     1               60               66              ---      ---       3.12        (2.67, 3.57)       \<0.001
  CD8 (%)                    2               91               94              99.2     \<0.001   -5.52       (-23.17, 12.13)    0.540
   *Ganoderma lucidum*       1               31               28              ---      ---       -14.59      (-17.61, -11.57)   \<0.001
   *Coriolus versicolor*     1               60               66              ---      ---       3.42        (2.79, 4.05)       \<0.001
  CD4/CD8                    3               106              109             99.7     \<0.001   0.73        (-0.45,1.91)       0.227
   *Ganoderma lucidum*       2               46               43              93.0     \<0.001   1.10        (0.15, 2.04)       0.024
   *Coriolus versicolor*     1               60               66              ---      ---       0.05        (0.04, 0.06)       \<0.001
  NK (%)                     2               30               30              55.1     0.135     5.87        (-1.06,12.80)      0.097
   *Ganoderma lucidum*       1               15               15              ---      ---       3.04        (-1.76, 7.84)      0.215
   *Coriolus versicolor*     1               15               15              ---      ---       10.29       (2.07, 18.51)      0.014
  KPS score\*                                                                                                                   
  Effective rate                                                                                                                
   *Ganoderma lucidum*       3               75               71              25.7     0.261     1.66        (1.21, 2.26)       \<0.001
  Stable rate                                                                                                                   
   *Ganoderma lucidum*       3               75               71              36.8     0.206     1.50        (1.09, 1.16)       0.001

KPS, Karnofsky Performance Status; \*, using RR.

###### 

Subgroup analysis of efficacy of the products for cancer type.

  ------------------------------------------------------------------------------------------------------------------------------------------
  Variable                      No. of trials   No. of subject   Heterogeneity   MD/\    95% *CI*   *P* value                      
                                                                                 RR/HR                                             
  ----------------------------- --------------- ---------------- --------------- ------- ---------- ----------- ------------------ ---------
  Overall survival                                                                                                                 

   Breast cancer                5               706              714             0.0     0.770      0.95        (0.65, 1.40)       0.798

   Colorectal cancer            2               230              232             87.2    0.005      1.22        (0.46, 3.21)       0.694

   Esophageal cancer            2               94               80              0.0     0.597      0.84        (0.57, 1.24)       0.387

   Gastric cancer               4               569              588             0.0     0.620      0.74        (0.62, 0.87)       0.001

   Hepatocellular carcinoma\*   1               9                6               ---     ---        0.35        (0.10, 1.23)       0.101

   Nasopharyngeal carcinoma\*   2               139              93              0.0     0.884      0.68        (0.56, 0.84)       \<0.001

   NSCLC                        2               60               56              0.0     1.000      0.99        (0.71, 1.38)       0.953

   Rectal cancer                1               53               53              ---     ---        1.82        (0.38, 8.72)       0.454

  Relapse-free survival rate                                                                                                       

   Breast cancer                5               706              714             0.0     0.572      1.18        (0.89, 1.57)       0.243

   Colorectal cancer            2               230              232             90.5    0.001      1.05        (0.42, 2.58)       0.923

   Gastric cancer\*             1               129              124             ---     ---        1.52        (1.01, 2.30)       0.046

   Hepatocellular carcinoma     1               9                6               ---     ---        0.42        (0.13, 1.36)       0.147

   Nasopharyngeal carcinoma     1               17               17              ---     ---        1.19        (0.45, 3.10)       0.729

   Rectal cancer                1               53               53              ---     ---        2.45        (0.99, 6.06)       0.053

  Clinical efficacy                                                                                                                

  Total efficacy                                                                                                                   

   Colorectal cancer            1               27               26              ---     ---        1.20        (0.71, 2.06)       0.497

   Gastrointestinal cancer      2               84               60              0.0     0.959      1.27        (0.79, 2.04)       0.329

   Nasopharyngeal carcinoma     1               122              76              ---     ---        1.16        (0.91, 1.47)       0.238

   NSCLC\*                      5               121              114             41.8    0.161      1.55        (1.12, 2.17)       0.009

  Control rate                                                                                                                     

   Colorectal cancer            1               27               26              ---     ---        1.06        (0.80, 1.40)       0.684

   Gastrointestinal cancer      2               84               60              0.0     0.803      0.97        (0.75, 1.26)       0.836

   Nasopharyngeal carcinoma     1               122              76              ---     ---        0.90        (0.77, 1.05)       0.182

   NSCLC\*                      5               155              148             0.0     0.623      1.18        (1.04, 1.33)       0.009

  Immunomodulating effects                                                                                                         

  CD3                                                                                                                              

   Colorectal cancer            1               15               15              ---     ---        10.44       (4.22, 16.66)      0.001

   Gastric cancer               1               60               66              ---     ---        4.30        (3.63, 4.97)       \<0.001

   NSCLC                        1               31               28              ---     ---        13.64       (10.67, 16.61)     \<0.001

  CD4\*                                                                                                                            

   Colorectal cancer            1               15               15              ---     ---        11.05       (5.75, 16.35)      \<0.001

   Gastric cancer               1               60               66              ---     ---        3.12        (2.67, 3.57)       \<0.001

   NSCLC                        1               31               28              ---     ---        13.89       (10.85, 16.93)     \<0.001

  CD8\*                                                                                                                            

   Gastric cancer               1               60               66              ---     ---        3.42        (2.79, 4.05)       \<0.001

   NSCLC                        1               31               28              ---     ---        -14.59      (-17.61, -11.57)   \<0.001

  CD4/CD8\*                                                                                                                        

   Colorectal cancer            1               15               15              ---     ---        0.58        (0.09, 1.07)       0.020

   Gastric cancer               1               60               66              ---     ---        0.05        (0.04, 0.06)       \<0.001

   NSCLC                        1               31               28              ---     ---        1.55        (1.44, 1.67)       \<0.001

  NK                                                                                                                               

   Colorectal cancer            1               15               15              ---     ---        3.04        (-1.76, 7.84)      0.215

   Gastric cancer\*             1               15               15              ---     ---        10.29       (2.07, 18.51)      0.014

  KPS score\*                                                                                                                      

  Effective rate                                                                                                                   

   Colorectal cancer            1               15               15              ---     ---        2.00        (0.76, 5.24)       0.159

   NSCLC                        2               60               56              54.1    0.140      1.60        (1.16, 2.21)       0.004

  Stable rate                                                                                                                      

   Colorectal cancer            1               15               15              ---     ---        1.30        (0.86, 1.96)       0.209

   NSCLC\*                      2               60               56              60.4    0.112      1.62        (1.27, 2.04)       \<0.001
  ------------------------------------------------------------------------------------------------------------------------------------------

NSCLC, Non-small cell lung cancer. \*P \< 0.05 means statistically significant.

Subgroup analysis for experiment type of CD3 showed the favorable effect on elevating the levels of CD3 both for trials using *G. lucidum* related natural products (*MD*: 13.05%; 95% *CI*: 10.37, 15.72; *P* \< 0.001; two trials) and *C. versicolor* related natural products (*MD*: 4.30%; 95% *CI*: 3.63, 4.97; *P* \< 0.001; one trials) compared with control group. The subgroup analysis of CD4 was consistent with CD3; trials using *G. lucidum* related natural products (*MD*: 13.19%; 95% *CI*: 10.55, 15.82; *P* \< 0.001; two trials) or *C. versicolor* related natural products (MD: 3.12%; 95% *CI*: 2.67, 3.57; *P* \< 0.001; one trials) had favorable effect on elevating the levels of CD4 ([**Table 2**](#T2){ref-type="table"}).

Subgroup analysis for experiment type of CD8 showed the favorable effect on felling the level of CD8 both for one trial using *G. lucidum* related natural products (MD: -14.59%; 95% *CI*: -17.61, -11.57; *P* \< 0.001) and one trial using *C. versicolor* related natural products (*MD*: 3.42%; 95% *CI*: 2.79, 4.05; *P* \< 0.001) compared with the control group. Subgroup analysis of CD4/CD8 showed the favorable effect on elevating the levels of CD4/CD8 both for trials using *G. lucidum* related natural products (*MD*: 1.1 95% *CI*: 0.15, 2.04; *P* = 0.024; two trials) and *C. versicolor* related natural products (*MD*: 0.05; 95% *CI*: 0.04, 0.06; *P* \< 0.001; one trials) compared with the control group ([**Table 2**](#T2){ref-type="table"}).

[**Table 3**](#T3){ref-type="table"} summarizes results of subgroup analyses for cancer type and immunomodulating effects. There was one trial that reported that *C. versicolor* and *G. lucidum* related natural products had a favorable effect on elevating the levels of CD3, CD4, and CD4/CD8 in colorectal cancer, gastric cancer, and NSCLC, respectively. One trial in gastric cancer reported that the products had a favorable effect on elevating the levels of CD8, but one trial in NSCLC reported that the products had an effect on felling the levels of CD8 ([**Table 3**](#T3){ref-type="table"}).

Post-Treatment KPS Score Change {#s4_4}
-------------------------------

Three trials using *G. lucidum* related natural products were compared with the post-treatment KPS score change. Compared with the control treatment, using *G. lucidum* related natural products was associated with a higher total efficacy (*RR*: 1.66; 95% *CI*: 1.21, 2.26; *P* \< 0.001) and higher stable rate (*RR*: 1.50; 95% *CI*: 1.09, 1.16; *P* = 0.001) ([**Table 2**](#T2){ref-type="table"}). Subgroup analyses for cancer type showed, compared with control treatment, that using *G. lucidum* related natural products was associated with a higher total efficacy (*RR*: 1.60; 95% *CI*: 1.16, 2.21; *P* = 0.004; two trials) and higher stable rate (*RR*: 1.62; 95% *CI*: 1.27, 2.04; *P* \< 0.001; two trials) in NSCLC. However, one trial reported the association between *G. lucidum* related natural products and post-treatment KPS score change in colorectal cancer ([**Table 3**](#T3){ref-type="table"}).

Adverse Events {#s4_5}
--------------

In all 23 trials, one trial in gastric cancer mentioned the severe adverse events ([@B32]); seven trials (two in NSCLC; one in breast cancer; one in nasopharyngeal carcinoma; one in gastric cancer; two in colorectal cancer) reported that adverse effects fell by using *C. versicolor* and *G. lucidum* related natural products ([@B21]; [@B13]; [@B38]; [@B39]; [@B43]; [@B44]; [@B18]). The most common adverse effects happened in including nausea or/and vomiting, leucopenia, diarrhea, thrombocytopenia, liver dysfunction, general fatigue, and anorexia.

Publication Bias and Sensitivity Analyses {#s4_6}
-----------------------------------------

Visual inspection of funnel plots ([**Figure 6**](#f6){ref-type="fig"}), Begg's test (*P* = 0.294), and Egger's test (*P* = 0.162) revealed no evidence of publication bias for the examined primary outcomes. We did sensitivity analyses by excluding four trials using the decoction ([@B15]; [@B43]; [@B14]; [@B9]); effects on OS (*HR*: 0.81; 95% *CI*: 0.69, 0.93; *P* = 0.004), total efficacy (*RR*: 1.26; 95% *CI*: 1.04, 1.53; *P* = 0.018), and control rate (*RR*: 1.00; 95% *CI*: 0.90, 1.11; *P* = 0.957) showed that the results did not change.

![Funnel plots of overall survival.](fphar-10-00703-g006){#f6}

Discussion {#s5}
==========

To the best of our knowledge, this study is the first meta-analysis focusing on *C. versicolor* and *G. lucidum* related natural products as adjuvant treatment on cancer patients. The pooled analysis demonstrated that *C. versicolor* and *G. lucidum* related natural products were significantly associated with lower risks of mortality in patients with cancers, and the pooled *HR* of patient in both groups is 0.82. Moreover, the effect on RFS is only available for *C. versicolor* related trials and results no significant difference across the patients. The side effect profiles show that these products were well tolerated. As a result, from aspects of clinical efficacy and safety, this study suggested that both *C. versicolor* and *G. lucidum* related therapy can be considered as an additional treatment option over different stages and types of cancers, although this recommendation cannot be specifically conclusive because the review only included limited kinds and stages of cancers.

With more evidence proving the anticancer effect of *C. versicolor* and *G. lucidum* extracts, lack of guidelines to support the clinical use for patients with cancers gradually becomes an issue. Especially in Asia, several companies have been dedicated to prepare anti-cancer formulae from *C. versicolor* and *G. lucidum* extracts using new technology ([@B27]). As the companies put huge amount of resources in marketing, as supplements, there is a booming demand of *C. versicolor* and *G. lucidum* related natural products for preventing and treating of cancers, and thus more companies are expected to participate in the potential market. However, based on the amount of clinical trials found in this review study, it is necessary to accelerate human trials of *C. versicolor* and *G. lucidum* extracts to verify their efficacy and safety in various types and stages of cancers. For cancer patients and their families, clinical evidence and guidelines recommending *C. versicolor* and *G. lucidum* related natural products as an additional treatment with conventional cancer therapies are critical to improve the survival chance. In this study, meta-analysis on the immunomodulating effects also showed that both *C. versicolor* and *G. lucidum* extracts can significantly elevate the levels of CD3 and CD4 T cell. The CD3 and CD4 T cell count alongside other immunological parameters are critical in monitoring immune function, and the CD4 T cell subset is used as a standard for assessing the progression of disease. Lower levels of CD3 and CD4 T cell are related to immunosuppression of chemotherapy or radiotherapy ([@B36]). The results of increasing the levels of CD3 and CD4 indicated that these products can help to reduce the immunosuppression of chemotherapy or radiotherapy.

The anticancer values of *C. versicolor* and *G. lucidum* have progressed for decades since the analysis of their extracts. Regarding the fact that clinicians usually confuse *C. versicolor* and *G. lucidum* since their dried herbs have similar appearance and nature of medicinals, this review has demonstrated distinguishable benefit of *C. versicolor* and *G. lucidum* extracts in different types and stages of cancer therapies as supplements. However, one of the best ways to prevent confusion is to promote proprietary Chinese medicine, for instance, capsule, pill, or dissolvable granule, and develop regular drugs for regions outside of East Asia. Learnt from this review, the future direction of *C. versicolor* and *G. lucidum* extract trials can be aimed to compare efficacy based on different standard dosages, or their independent therapeutic effect on patients with end stage cancers.

Several limitations are encountered during this study. First, the number of clinical trials is limited and mainly conducted in Asia. There is a lack of a large number of patients with the same type and stage of cancer, and the generalizability is limited. Second, the *C. versicolor* and *G. lucidum* extracts in trials are prepared differently and with various dosages. Therefore, we could not effectively examine the dosage effect of treatment across the outcomes. Third, although the adverse events (AE)/serious adverse events (SAE) profile is an important factor for choosing treatment options, it was not possible to perform an analysis to deal with such a concern because AE/SAE are not fully reported in all included trials. Fourth, we lack the dose-response analysis of these products because most of the original data did not mention the dose response; we could not conduct the dose-response analysis. In addition, as some patients are undergoing post-surgery and/or radiotherapy or chemotherapy, causation between the events and *C. versicolor* and *G. lucidum* extracts is hard to be evaluated. Fourth, in the included trials, *C. versicolor* and *G. lucidum* extracts can be independently applied or combined with other drugs as interventions; therefore, some of the therapeutic effect can be due to the interacted result between *C. versicolor* and *G. lucidum* extracts and other components.

Conclusion {#s6}
==========

In this meta-analysis, we found that *C. versicolor* and *G. lucidum* related natural products could increase the OS in cancer patients. Besides, it seems likely that the products provide clinical and life quality benefits for cancer patients with low side effects. Large sample size and high-quality randomized controlled trial (RCT) in different continents with various types and stages of cancer are needed to further evaluate the effect of the products on patients in the future.
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